Reviewing Alimera Sciences (ALIM) & Argos Therapeutics (ARGS)
Alimera Sciences (NASDAQ: ALIM) and Argos Therapeutics (NASDAQ:ARGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations.
Earnings and Valuation
This table compares Alimera Sciences and Argos Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Alimera Sciences||$35.91 million||2.33||-$33.17 million||($0.32)||-3.78|
|Argos Therapeutics||$950,000.00||9.24||-$53.02 million||($25.20)||-0.06|
Risk & Volatility
Alimera Sciences has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Argos Therapeutics has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500.
Insider & Institutional Ownership
46.2% of Alimera Sciences shares are owned by institutional investors. 14.7% of Alimera Sciences shares are owned by company insiders. Comparatively, 28.2% of Argos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Alimera Sciences and Argos Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings for Alimera Sciences and Argos Therapeutics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Alimera Sciences currently has a consensus target price of $4.00, indicating a potential upside of 230.58%. Argos Therapeutics has a consensus target price of $24.00, indicating a potential upside of 1,578.32%. Given Argos Therapeutics’ higher possible upside, analysts clearly believe Argos Therapeutics is more favorable than Alimera Sciences.
Alimera Sciences beats Argos Therapeutics on 9 of the 12 factors compared between the two stocks.
About Alimera Sciences
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
About Argos Therapeutics
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.